Partnered products

4SC has out-licensed and partnered drug candidates to several national and international pharma and biotech companies.

Licensed to BioNTech AG

Toll-like receptor 7 (TLR-7) is limited to immune cells and activates the immune system to kill cancer cells. The anti-tumor activity of 4SC’s immune stimulators has been demonstrated in several animal studies.

December 2009
Journal of Immunotoxicology
Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.

Hamm S, Rath S, Michel S, Baumgartner R.

J Immunotoxicol. 2009 Dec;6(4):257-65. doi: 10.3109/15476910903286733.


Share this page:

Follow us on: